Researchers from Henan University of Chinese Medicine have reported the discovery and preclinical evaluation of new histone lysine-specific demethylase 1 (LSD1) inhibitors as potential anticancer candidates.
Rain Oncology Inc.’s only asset failed a pivotal phase III study for treating dedifferentiated liposarcoma, casting shadows on the future of the small molecule and the company’s direction. Milademetan, an oral inhibitor of the MDM2-p53 complex that reactivates p53, missed the Mantra study’s primary endpoint of progression-free survival compared to the standard of care treatment, Yondelis (trabectedin, Johnson & Johnson/Pharmamar SA).
A Voronoi Bio Inc. and Voronoi Inc. patent describes platelet-derived growth factor receptor (PDGFR), mast/stem cell growth factor receptor kit (KIT; c-Kit; CD117) and their mutant inhibitors reported to be useful for the treatment of cancer, fibrosis, neurological diseases, atherosclerosis, and pulmonary hypertension.
Researchers from City of Hope discussed preclinical data for CD33-targeted chimeric antigen receptor (CAR) T cells being developed for the treatment of acute myeloid leukemia (AML).
Five months after the first anti-CD20xCD3 T-cell engaging bispecific antibody, Roche Holding AG’s Lunsumio (mosunetuzumab), cleared U.S. FDA approval for follicular lymphoma, partners Genmab A/S and Abbvie Inc. won the agency’s approval for epcoritamab as the first subcutaneous CD20xCD3 bispecific antibody for treating diffuse large B-cell lymphoma.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has divulged exportin-1 (CRM1; XPO1) receptor antagonists reported to be useful for the treatment of lymphoma and leukemia.
Acerand Therapeutics (Hong Kong) Ltd. has identified tetrahydrofuran-containing polycyclic derivatives and their pharmaceutically acceptable salts reported to be useful for the treatment of ovarian cancer.
Bolt Biotherapeutics Inc. has synthesized antibody-drug conjugates (ADCs) comprising cysteine-mutant antibodies targeting programmed cell death 1 ligand 1 (CD274; PD-L1) covalently bound to one or more Toll-like receptor 7 (TLR7) and/or TLR8 agonists through a linker reported to be useful for the treatment of cancer.
Distant metastasis and drug resistance are the main causes of colorectal cancer (CRC)-derived mortality. Identifying the underlying mechanisms driving metastasis is key for improving its therapy. Epithelial-to-mesenchymal transition (EMT) promotes the migration and invasion of tumor cells, allowing them to metastasize distant organs. Chinese researchers put the focus on dishevelled segment polarity protein 3 (DVL3) due to its involvement in the Wnt signaling pathway.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
